Sign inJoin waitlistJoin the waitlist

JW

Jeffrey Weber

Credentials: · · · · ·

History

Medical Oncology
1978–1980
Internal Medicine
1975–1978
New York University Grossman School of Medicine
1971–1975

Research

Improved survival with ipilimumab in patients with metastatic melanoma
New England Journal of Medicine · 2010 · 12,191 citations
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
New England Journal of Medicine · 2011 · 3,572 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2018 · 2,915 citations

Omid Hamid
37 papers
Jedd Wolchok
35 papers
Stephen Hodi
33 papers
SO
Steven O'Day
24 papers
Vernon Sondak
23 papers
AS
Amod Sarnaik
22 papers
Anna Pavlick
22 papers
IO
Iman Osman
21 papers
Adil Daud
20 papers
Antoni Ribas
20 papers
Geoffrey Gibney
20 papers
RG
Rene Gonzalez-Cotarelo
19 papers

Grants

K12 Training for Clinical and Translational Oncology Researchers
National Cancer Institute · K12
Contact PI · $53.5K · New York University School of Medicine
2023–2028
NYU Melanoma SPORE
National Cancer Institute · P50
PI · $12.5M · New York University School of Medicine
2019–2026
Correlative Biomarkers of IL-6 Blockade Combined with Checkpoint Inhibition
National Cancer Institute · R01
Contact PI · $2.4M · New York University School of Medicine
2020–2025
(8) Genomic Determinants of the T-Cell Regulome in Immune Checkpoint Blockade
National Cancer Institute · R01
PI · $3M · New York University School of Medicine
2018–2024

Clinical trials

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
Principal investigator · Terminated · Phase 1, Phase 2
NYU Langone Health
2018
A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Principal investigator · Terminated · Phase 1
NYU Langone Health
2018–2020
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
Principal investigator · Completed · Phase 2
NYU Langone Health
2016–2022
Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma
Principal investigator · Completed · Phase 1
NYU Langone Health
2016–2021